Equities

Medrx Co Ltd

4586:TYO

Medrx Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)90.00
  • Today's Change-1.00 / -1.10%
  • Shares traded219.00k
  • 1 Year change-47.67%
  • Beta2.2384
Data delayed at least 20 minutes, as of Nov 13 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,7219941,704
Total Receivables, Net331523
Total Inventory108.3412
Prepaid expenses11548.65
Other current assets, total10157.66
Total current assets1,7851,0871,755
Property, plant & equipment, net182226270
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term2.292.29--
Other long term assets383840
Total assets2,0521,3982,109
LIABILITIES
Accounts payable------
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total100158126
Total current liabilities100158126
Total long term debt000
Total debt000
Deferred income tax4.925.065.21
Minority interest------
Other liabilities, total232222
Total liabilities128186153
SHAREHOLDERS EQUITY
Common stock8482277,804
Additional paid-in capital1,9163,0637,373
Retained earnings (accumulated deficit)(849)(2087)(13220)
Treasury stock - common00--
Unrealized gain (loss)------
Other equity, total118.72(0.97)
Total equity1,9251,2131,955
Total liabilities & shareholders' equity2,0521,3982,109
Total common shares outstanding382825
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.